

QUALIFICATION IN IMMUNOHISTOCHEMISTRY (QIHC) PRACTICE EXAM (SAMPLE)

STUDY GUIDE



**SAMPLE STUDY GUIDE
WITH LIMITED QUESTIONS**

**VISIT US ONLINE FOR
THE FULL VERSION STUDY GUIDE**

<https://qihc.examzify.com>



Copyright © 2026 by Examzify - A Kaluba Technologies Inc. product.

ALL RIGHTS RESERVED.

No part of this book may be reproduced or transferred in any form or by any means, graphic, electronic, or mechanical, including photocopying, recording, web distribution, taping, or by any information storage retrieval system, without the written permission of the author.

Notice: Examzify makes every reasonable effort to obtain accurate, complete, and timely information about this product from reliable sources.

SAMPLE

Table of Contents

Copyright	1
Table of Contents	2
Introduction	3
How to Use This Guide	4
Questions	5
Answers	8
Explanations	10
Next Steps	16

SAMPLE

Introduction

Preparing for a certification exam can feel overwhelming, but with the right tools, it becomes an opportunity to build confidence, sharpen your skills, and move one step closer to your goals. At Examzify, we believe that effective exam preparation isn't just about memorization, it's about understanding the material, identifying knowledge gaps, and building the test-taking strategies that lead to success.

This guide was designed to help you do exactly that.

Whether you're preparing for a licensing exam, professional certification, or entry-level qualification, this book offers structured practice to reinforce key concepts. You'll find a wide range of multiple-choice questions, each followed by clear explanations to help you understand not just the right answer, but why it's correct.

The content in this guide is based on real-world exam objectives and aligned with the types of questions and topics commonly found on official tests. It's ideal for learners who want to:

- Practice answering questions under realistic conditions,
- Improve accuracy and speed,
- Review explanations to strengthen weak areas, and
- Approach the exam with greater confidence.

We recommend using this book not as a stand-alone study tool, but alongside other resources like flashcards, textbooks, or hands-on training. For best results, we recommend working through each question, reflecting on the explanation provided, and revisiting the topics that challenge you most.

Remember: successful test preparation isn't about getting every question right the first time, it's about learning from your mistakes and improving over time. Stay focused, trust the process, and know that every page you turn brings you closer to success.

Let's begin.

How to Use This Guide

This guide is designed to help you study more effectively and approach your exam with confidence. Whether you're reviewing for the first time or doing a final refresh, here's how to get the most out of your Examzify study guide:

1. Start with a Diagnostic Review

Skim through the questions to get a sense of what you know and what you need to focus on. Your goal is to identify knowledge gaps early.

2. Study in Short, Focused Sessions

Break your study time into manageable blocks (e.g. 30 – 45 minutes). Review a handful of questions, reflect on the explanations.

3. Learn from the Explanations

After answering a question, always read the explanation, even if you got it right. It reinforces key points, corrects misunderstandings, and teaches subtle distinctions between similar answers.

4. Track Your Progress

Use bookmarks or notes (if reading digitally) to mark difficult questions. Revisit these regularly and track improvements over time.

5. Simulate the Real Exam

Once you're comfortable, try taking a full set of questions without pausing. Set a timer and simulate test-day conditions to build confidence and time management skills.

6. Repeat and Review

Don't just study once, repetition builds retention. Re-attempt questions after a few days and revisit explanations to reinforce learning. Pair this guide with other Examzify tools like flashcards, and digital practice tests to strengthen your preparation across formats.

There's no single right way to study, but consistent, thoughtful effort always wins. Use this guide flexibly, adapt the tips above to fit your pace and learning style. You've got this!

Questions

SAMPLE

- 1. What does antibody diluent influence in IHC development?**
 - A. Color of the stain
 - B. Antibody concentration matters more than anything else.
 - C. Antibody conformation is unaffected.
 - D. Antibody conformation stability and Fc non-specific interactions.
- 2. Which of the following is NOT listed as a factor contributing to background staining in IHC?**
 - A. Endogenous enzymes
 - B. Insufficient blocking
 - C. Specific to target antigen and antibody reaction or detection method
 - D. Non-specific binding due to cross-reactivity
- 3. Which enzymes are used for intracellular antigen exposure in immunohistochemistry?**
 - A. Trypsin 0.05% to 0.1% 37°C (10 to 40 min)
 - B. Proteinase K 20 µg/mL 37°C (20 min)
 - C. Pepsin 0.40% 37°C (30 to 180 min)
 - D. All of the above
- 4. Which T cell subset suppresses immune responses?**
 - A. Suppressor T cells
 - B. Helper T cells
 - C. Cytotoxic T cells
 - D. B cells
- 5. Which markers are included in the Pan-Mel + S100 panel?**
 - A. Tyrosinase -T311 Malignant melanoma- cyto; MART-1 Malignant Melanoma-Cyto; S100 Malignant Melanoma-Nuc/Cyto
 - B. Tyrosinase, CK7, S100
 - C. MART-1, S100, Ki-67
 - D. Tyrosinase, MART-1, CK20

- 6. Which statement best describes the interpretation basis for qualitative IHC results?**
- A. By the number of positive cells alone
 - B. By the standard staining protocol duration
 - C. By the correct cellular localization of the staining reaction and staining of the correct tissue structures
 - D. By the overall color tone of the slide
- 7. Which marker is a B-cell transcription factor used as a marker in immunophenotyping?**
- A. CD20
 - B. Pax-5
 - C. CD3
 - D. CD56
- 8. Which of the following best defines a tumor?**
- A. A malignant cell
 - B. A mass of abnormal cells that develops when cancerous cells divide and grow uncontrollably
 - C. An immune cell
 - D. A normal tissue
- 9. Which term describes the spread of cancer cells to distant sites?**
- A. Local tissue growth only
 - B. Spread to distant locations
 - C. Regression
 - D. Remission
- 10. Which statement correctly describes an antibody?**
- A. Protein produced by B lymphocytes that attaches to a specific antigen.
 - B. A lipid that forms membranes.
 - C. A carbohydrate that stores energy.
 - D. A nucleotide.

Answers

SAMPLE

1. D
2. D
3. D
4. A
5. A
6. C
7. B
8. B
9. B
10. A

SAMPLE

Explanations

SAMPLE

1. What does antibody diluent influence in IHC development?

- A. Color of the stain
- B. Antibody concentration matters more than anything else.
- C. Antibody conformation is unaffected.
- D. Antibody conformation stability and Fc non-specific interactions.**

The main point here is that the diluent helps maintain the antibody as a stable, properly folded protein and reduces non-specific Fc interactions that can cause background staining. A well-chosen diluent preserves the antibody's conformation so its antigen-binding site remains correctly shaped to recognize the target epitope. It also lowers Fc-mediated non-specific binding by including blocking proteins, appropriate salts, and sometimes detergents, which together reduce background and improve specificity. The color you see comes from the chromogen, not the diluent, and while dilution is important, the diluent's ability to keep the antibody stable and minimize Fc-related background is what most directly influences the quality of the signal. So the best answer highlights both antibody conformation stability and Fc non-specific interactions.

2. Which of the following is NOT listed as a factor contributing to background staining in IHC?

- A. Endogenous enzymes
- B. Insufficient blocking
- C. Specific to target antigen and antibody reaction or detection method
- D. Non-specific binding due to cross-reactivity**

Background staining in IHC comes from non-specific interactions that obscure or mask the true signal. Two classic contributors are endogenous enzymes in the tissue (which can produce color without the target antigen) and insufficient blocking (which leaves sites that readily bind antibodies non-specifically). These are straightforward to address with proper blocking steps and enzyme quenching. The option describing non-specific binding due to cross-reactivity is pointing to a different issue—antibody specificity. Cross-reactivity means the antibody binds to unintended proteins that resemble the target, which can cause misleading signals. In many teaching lists, this crosses from the category of background staining into a separate consideration about antibody quality and specificity rather than a listed background-causing factor. That's why this item is treated as not being a background-staining factor in this context. In practice, to reduce cross-reactivity you'd validate antibodies rigorously, use well-characterized clones, possibly pre-adsorb antibodies, and include appropriate controls.

3. Which enzymes are used for intracellular antigen exposure in immunohistochemistry?

- A. Trypsin 0.05% to 0.1% 37°C (10 to 40 min)
- B. Proteinase K 20 µg/mL 37°C (20 min)
- C. Pepsin 0.40% 37°C (30 to 180 min)

D. All of the above

Enzymatic antigen retrieval uses proteolytic digestion to unmask epitopes that are hidden by formalin cross-links, making intracellular targets accessible to antibody binding. Trypsin, proteinase K, and pepsin are all proteases commonly used for this purpose, each under specific conditions to suit different antigens and tissues. Trypsin digests proteins at Lys-Arg sites and is effective for exposing cytoplasmic and some membrane-associated antigens. Proteinase K provides broad proteolysis and is particularly useful when more robust or nuclear intracellular epitopes need exposure. Pepsin, active in acidic conditions, can reveal certain intracellular epitopes that respond to gentler but acidic proteolysis. Because each enzyme can be employed for intracellular antigen exposure depending on the antigen, tissue, and fixation, using all of them covers the range of scenarios encountered in practice.

4. Which T cell subset suppresses immune responses?

A. Suppressor T cells

- B. Helper T cells
- C. Cytotoxic T cells
- D. B cells

The immune response is finely balanced by regulatory mechanisms, and the subset that suppresses immune activity is the regulatory T cell, often described as suppressor T cells. These cells act to dial down activation of other T cells and effector responses after an infection or challenge, helping prevent excessive inflammation and autoimmunity. They can dampen responses through direct cell-to-cell interactions and by releasing inhibitory cytokines such as IL-10 and TGF-β, and they typically express markers like FOXP3 (with CD4 and CD25 in humans). In tissue studies, FOXP3+ cells within the CD4+ T cell population point to regulatory/suppressor activity. The other T cell types have opposite roles: helper T cells coordinate and amplify responses, cytotoxic T cells kill infected or malignant cells, and B cells produce antibodies. Therefore, the suppressor (regulatory) T cell is the one responsible for dampening immune responses.

5. Which markers are included in the Pan-Mel + S100 panel?

- A. Tyrosinase -T311 Malignant melanoma- cyto; MART-1 Malignant Melanoma-Cyto; S100 Malignant Melanoma-Nuc/Cyto**
- B. Tyrosinase, CK7, S100
- C. MART-1, S100, Ki-67
- D. Tyrosinase, MART-1, CK20

This item tests which markers are included in a Pan-Mel + S100 panel used in melanoma workups. The panel combines melanocytic differentiation markers with a highly sensitive melanocytic marker to confirm melanocytic lineage in tumors. Tyrosinase and MART-1 (Melan-A) are specific indicators of melanocytes and melanoma cells, while S100 is a very sensitive marker for melanocytic cells, often staining in melanoma even when other markers are negative. The combination of these three provides a strong, complementary signature for melanoma, which is why the option listing Tyrosinase, MART-1, and S100 best fits the Pan-Mel + S100 panel and matches the typical staining notes (cytoplasmic for Tyrosinase and MART-1, and nuclear/cytoplasmic for S100). The other choices bring in markers not used in this panel (such as CK7/CK20, which are epithelial markers, or Ki-67, a proliferation marker) or omit a key melanocytic marker, making them less appropriate for identifying melanocytic origin.

6. Which statement best describes the interpretation basis for qualitative IHC results?

- A. By the number of positive cells alone
- B. By the standard staining protocol duration
- C. By the correct cellular localization of the staining reaction and staining of the correct tissue structures**
- D. By the overall color tone of the slide

Interpreting qualitative IHC results hinges on where the stain appears, not how much staining you see. A true qualitative positive is defined by staining in the correct cellular compartment (for example, nuclear for a transcription factor, membrane for a receptor, or cytoplasmic for certain enzymes) and within the appropriate tissue structures. This subcellular and architectural localization confirms that the antibody is binding the intended antigen in the right cellular context, rather than producing random background signal. Relying on the number of positive cells or the overall color tone can be misleading, and the duration of the staining protocol is not what determines the interpretation. Staining that localizes to the wrong compartment or to non-target structures suggests non-specific or artifactual signal, even if some color is visible.

7. Which marker is a B-cell transcription factor used as a marker in immunophenotyping?

- A. CD20
- B. Pax-5**
- C. CD3
- D. CD56

This item tests recognizing a B-cell transcription factor used in immunophenotyping. Pax-5, also known as BSAP, is a nuclear transcription factor essential for B-cell development and maintenance. Because it resides in the nucleus, Pax-5 staining helps identify B-cell lineage even when surface markers are variable or downregulated, making it a reliable companion marker in immunophenotyping of lymphomas and other B-cell neoplasms. It is detectable as a nuclear stain, in contrast to surface markers like CD20, CD3, or CD56, which appear on the cell membrane. The other options are surface markers for different lineages (CD20 for mature B cells, CD3 for T cells, CD56 for NK cells), not transcription factors. Hence, Pax-5 is the B-cell transcription factor used as a marker in immunophenotyping.

8. Which of the following best defines a tumor?

- A. A malignant cell
- B. A mass of abnormal cells that develops when cancerous cells divide and grow uncontrollably**
- C. An immune cell
- D. A normal tissue

The idea being tested is what defines a tumor: a mass formed by abnormal, uncontrolled cell growth. Among the options, the description that a tumor is a mass of abnormal cells that develops when cells divide and grow uncontrollably best captures this concept. A single malignant cell isn't a tumor by itself, and immune cells or normal tissue don't form such an abnormal proliferating mass. It's also important to note that tumors can be benign or malignant—the term describes the growth as a mass of proliferating cells, while behavior like invasion or metastasis distinguishes malignant from benign growth.

9. Which term describes the spread of cancer cells to distant sites?

- A. Local tissue growth only
- B. Spread to distant locations**
- C. Regression
- D. Remission

Metastasis describes the spread of cancer cells to distant sites. Cancer cells may detach from the primary tumor, enter blood or lymphatic vessels, circulate, and colonize distant organs, forming secondary tumors. This is what makes cancer spread beyond the original location and influences prognosis and treatment choices. Local tissue growth only refers to growth at the original site and does not imply distant spread. Regression means a decrease in tumor size, and remission indicates no detectable disease after therapy. So, metastasis best describes spread to distant locations.

10. Which statement correctly describes an antibody?

A. Protein produced by B lymphocytes that attaches to a specific antigen.

B. A lipid that forms membranes.

C. A carbohydrate that stores energy.

D. A nucleotide.

Antibodies are proteins produced by B lymphocytes that bind specific antigens. Their specificity comes from variable regions that recognize unique shapes on antigens, allowing targeted neutralization or marking for immune attack. They are not lipids, carbohydrates, or nucleotides, which are other types of biomolecules. So the description of an antibody as a protein produced by B lymphocytes that attaches to a specific antigen correctly captures what antibodies are and how they function.

SAMPLE

Next Steps

Congratulations on reaching the final section of this guide. You've taken a meaningful step toward passing your certification exam and advancing your career.

As you continue preparing, remember that consistent practice, review, and self-reflection are key to success. Make time to revisit difficult topics, simulate exam conditions, and track your progress along the way.

If you need help, have suggestions, or want to share feedback, we'd love to hear from you. Reach out to our team at hello@examzify.com.

Or visit your dedicated course page for more study tools and resources:

<https://qihc.examzify.com>

We wish you the very best on your exam journey. You've got this!

SAMPLE